Arrowhead Research Corp  

(Public, NASDAQ:ARWR)   Watch this stock  
Find more results for Arrowhead Systems, Inc.�
6.44
-0.21 (-3.16%)
Real-time:   1:25PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.38 - 6.66
52 week 4.95 - 27.63
Open 6.64
Vol / Avg. 555,663.00/3.01M
Mkt cap 361.72M
P/E     -
Div/yield     -
EPS -1.15
Shares 54.73M
Beta 2.56
Inst. own 75%
Mar 3, 2015
Arrowhead Research Corp Annual Shareholders Meeting - 1:00PM EST - Add to calendar
Feb 20, 2015
Arrowhead Research Corp Annual Shareholders Meeting (Estimated) - 1:00PM EST - Add to calendar
Feb 2, 2015
Q1 2015 Arrowhead Research Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 3, 2014
Arrowhead Research Corp at Piper Jaffray Healthcare Conference
Dec 1, 2014
Arrowhead Research Corp at Deutsche Bank BioFEST
Nov 25, 2014
Q4 2014 Arrowhead Research Corp Earnings Call
Nov 25, 2014
Q4 2014 Arrowhead Research Corp Earnings Release
Nov 20, 2014
Arrowhead Research Corp at Jefferies Global Healthcare Conference - London
Nov 10, 2014
Arrowhead Research Corp Conference Call to discuss results of Phase 2a study of ARC-520 and ARC-AAT
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin -51269.78% -33557.38%
Operating margin -51095.57% -30443.59%
EBITD margin - -28433.29%
Return on average assets -47.42% -53.35%
Return on average equity -50.99% -60.43%
Employees 81 -
CDP Score - -

Address

Suite 1050, 225 South Lake Avenue
PASADENA, CA 91101
United States - Map
+1-626-3043400 (Phone)
+1-626-3043401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Arrowhead Research Corporation (Arrowhead) is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its drug delivery technologies to develop drugs based on the RNA interference mechanism that silences disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead�s pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. Arrowhead�s anti-obesity drug candidate, Adipotide, selectively destroys the blood supply that supports the growth of unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue. In April 2012, the Company acquired Alvos Therapeutics, Inc.

Officers and directors

Christopher Richard Anzalone Ph.D. President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Kenneth Allen Myszkowski Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Bruce D. Given M.D. Chief Operating Officer
Bio & Compensation  - Reuters
Douglass B. Given M.D., Ph.D. Director
Age: 61
Bio & Compensation  - Reuters
Mauro Ferrari Ph.D Independent Director
Age: 54
Bio & Compensation  - Reuters
Edward W. Frykman Independent Director
Age: 77
Bio & Compensation  - Reuters
Charles P. McKenney Independent Director
Age: 75
Bio & Compensation  - Reuters
Michael S. Perry Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters